Advanced Nuclear Medicine Ingredents
Develops radiometals labeled radiopharmaceuticals and a global service provider in the radiopharmaceutical field.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD9m (Public information from Nov 2018)
Company register number 0627.636.718
Liège Liège (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenues | <1m | 1.1m | 2.6m | 3.1m | 6.5m | - |
| % growth | - | 25 % | 147 % | 17 % | 114 % | - |
| EBITDA | (<1m) | (<1m) | (<1m) | (1.1m) | 1.0m | <1m |
| % EBITDA margin | (53 %) | (36 %) | (3 %) | (36 %) | 16 % | - |
| Profit | (<1m) | (<1m) | (<1m) | (1.2m) | <1m | <1m |
| % profit margin | (67 %) | (41 %) | (6 %) | (38 %) | 4 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
€5.2m Valuation: €5.2m 4.9x EV/LTM Revenues -13.8x EV/LTM EBITDA | Acquisition | ||
| Total Funding | - | ||